Your browser doesn't support javascript.
loading
Veno-arterial extracorporeal membrane oxygenation versus standard medical management for massive pulmonary embolism.
Kelty, Catherine E; Berjaoui, Wael; Shrestha, Nabin K; Fitch, Stephen; Jovinge, Stefan M; Rendon, Renzo Loyaga.
Afiliação
  • Kelty CE; Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, USA.
  • Berjaoui W; Pulmonary Medicine, Spectrum Health, Grand Rapids, MI, USA.
  • Shrestha NK; Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, USA.
  • Fitch S; Pulmonary Medicine, Spectrum Health, Grand Rapids, MI, USA.
  • Jovinge SM; Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI, USA.
  • Rendon RL; Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Perfusion ; : 2676591231182247, 2023 Jun 07.
Article em En | MEDLINE | ID: mdl-37283140
PURPOSE: There is limited research on the use and outcomes of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) treatment for massive pulmonary embolism (PE). This study compared VA-ECMO treatment for massive PE versus patients treated medically. MATERIALS AND METHODS: Patients diagnosed with massive PE at one hospital system were reviewed. VA-ECMO and non-ECMO groups were compared by t test and Chi-square. Mortality risk factors were identified by logistic regression. Survival was assessed by Kaplan Meier and propensity matching of groups. RESULTS: Ninety-two patients were included (22 VA-ECMO and 70 non-ECMO). Age (OR 1.08, 95% CI 1.03-1.13), arterial SBP (OR 0.97, 95% CI 0.94-0.99), albumin (OR 0.3, 95% CI 0.1-0.8), and phosphorus (OR 2.0, 95% CI 1.4-3.17) were independently associated with 30-day mortality. Alkaline phosphate (OR 1.03, 95% CI 1.01-1.05) and SOFA score (OR 1.3, 95% CI 1.06-1.51) were associated with 1-year mortality. Propensity matching showed no difference in 30-day (59% VA-ECMO versus 72% non-ECMO, p = 0.363) or 1-year survival (50% VA-ECMO versus 64% non-ECMO, p = 0.355). CONCLUSIONS: Patients treated with VA-ECMO for massive PE and medically treated patients have similar short- and long-term survival. Further research is needed to define clinical recommendations and benefits of intensive therapy such as VA-ECMO in this critically ill population.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article